Heart failure
HF · CVRM · 5 drugs · 4 indications
Impaired cardiac output. Includes HFrEF (reduced EF) and HFpEF (preserved EF).
Competitive Landscape (5 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| MariTide | AMGN | GLP-1 agonist / GIP antagonist (bispecific) | Antibody-peptide conjugate | SC | PHASE3 |
| Farxiga | AZN | SGLT2 inhibitor | Small molecule | ORAL | APPROVED |
| Entresto | NVS | ARNI (Angiotensin receptor-neprilysin inhibitor) | Small molecule | Oral | APPROVED |
| Jardiance | LLY | SGLT2 inhibitor | Small molecule | ORAL | APPROVED |
| Verquvo | MRK | sGC stimulator | Small molecule | PO | APPROVED |
Indications (4)
Heart Failure (worsening)
Heart failure with preserved ejection fraction
Heart failure with reduced ejection fraction
Upcoming Catalysts
MariTide - Obesity - Ph2 Part 2 - Maintenance/Quarterly Dosing DataCLINICAL
AMGNH1 2026
Entresto - Generic Competition ImpactCOMPETITIVE
NVS2026
MariTide - T2D + Obesity - Ph3 - Topline (MARITIME-2)CLINICAL
AMGNEarly 2027
MariTide - Obesity - Ph3 - Topline (MARITIME-1)CLINICAL
AMGNEarly 2027
MariTide - Obesity - BLA FilingREGULATORY
AMGN2027-2028
MariTide - HFpEF - Ph3 - Outcomes (MARITIME-HF)CLINICAL
AMGN2028+
Data from Supabase · Updated 2026-03-24